Key Highlights

  • USD 195.0 million in gross proceeds arrived in July 2026 when Denali Therapeutics (NASDAQ:DNLI) closed the sale of its rare pediatric disease priority review voucher.
  • USD 200.0 million in gross proceeds came in March 2026 from the synthetic Royalty funding agreement with Royalty Pharma, closed the same month as the AVLAYAH approval.
  • March 24, 2026 was the date the FDA granted Accelerated Approval to AVLAYAH, and commercial distribution began in April 2026.
  • Two setbacks hit in 2026: the Phase 2b LUMA Parkinson's study missed its endpoints in May, and Takeda ended the DNL593 collaboration effective June.

A Voucher Sale Follows the AVLAYAH Approval

Denali Therapeutics (NASDAQ:DNLI) filed its Quarterly Report for the period ended September 30, 2026 on November 3, 2026. The filing confirms that the FDA granted AVLAYAH accelerated approval on March 24, 2026 for neurologic manifestations of Hunter syndrome, also called MPS II, in eligible pediatric patients weighing at least 5 kg. Commercial distribution began in April 2026. With the approval came a rare pediatric disease priority review voucher, which the company agreed to sell in June 2026 for USD 195.0 million in gross proceeds. The sale closed and the cash was received in July 2026. A voucher shortens the FDA review clock on a future application, so buyers pay for time saved.

Blood-Brain Barrier Platform and the Funding Stack

Denali describes AVLAYAH as the first FDA-approved biologic designed to cross the blood-brain barrier and reach the whole body, including the brain. The delivery technology is the company's Transport Vehicle platform, and the same approach supports programs in Sanfilippo syndrome type A, Pompe disease, frontotemporal dementia and Alzheimer's disease. In March 2026 the company also closed a synthetic royalty funding agreement with Royalty Pharma, receiving USD 200.0 million in gross proceeds. In simple terms, such an arrangement exchanges a share of future product Revenue for cash today, which funds development without selling new shares. Together, the two transactions bring USD 395.0 million in gross proceeds in 2026 (simple arithmetic on the two published figures, before fees and any repayment obligations). The extract did not include the cash balance or net loss, so they are not stated.

Confirmatory Trial, Setbacks and What to Watch

The approval rests on a surrogate endpoint, a reduction in cerebrospinal fluid heparan sulfate, and continued approval depends on confirming clinical benefit in the ongoing global Phase 2/3 COMPASS trial. That makes COMPASS the central risk, since a weak confirmatory result could affect the label. The year also brought setbacks. In May 2026 the Phase 2b LUMA study of BIIB122/DNL151, run with Biogen in early-stage Parkinson's disease, missed its primary and secondary endpoints, and development in idiopathic Parkinson's was discontinued. In April 2026 Takeda notified Denali it would end the DNL593 collaboration, effective June 2026, which the filing says was driven by strategic considerations and not by efficacy or safety data. Rights reverted to Denali. The filing also lists reimbursement and market acceptance among the risks.

Where Things Stand

Denali Therapeutics (NASDAQ:DNLI) booked the USD 195.0 million because the FDA approval of AVLAYAH on March 24, 2026 produced a priority review voucher that the company chose to sell, with the cash received in July 2026. The balance of evidence is mixed: the approval and USD 395.0 million of combined 2026 proceeds (simple arithmetic) strengthen the funding position, while the confirmatory COMPASS trial, the failed LUMA study and the loss of Takeda as a DNL593 partner add risk. The filing did not provide the figures needed to judge how long the cash lasts, so next steps to watch are launch progress, COMPASS updates and the BEACON study.